Incet

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Incet

Property Description
Active ingredient Levocetirizine Dihydrochloride
Forms Tablets, film-coated tablets, oral solution
Pharmacological class Second-generation Antihistamine
Common use Relief of allergic symptoms
Origin Synthetic (R-enantiomer of Cetirizine)

What is Incet and Its Active Ingredient?

Incet is a pharmaceutical product intended for oral administration whose active ingredient is Levocetirizine Dihydrochloride, a compound clinically recognized as a highly effective second-generation antihistamine.

This medication is a synthetic, single-ingredient product derived from the antihistamine Cetirizine. Levocetirizine is specifically the R-enantiomer—the pharmacologically active isomer—and the active metabolite of the parent compound. This formulation represents a focused chemical development, establishing its role in targeted relief for allergic discomfort. Incet is commonly formulated into tablets, film-coated tablets, and an oral solution to accommodate different patient populations and administration preferences.

How is Incet Pharmacologically Classified?

Incet (Levocetirizine) belongs to the second-generation antihistamine class, functioning as a highly selective peripheral H₁-receptor antagonist.

This precise classification means the drug's action is intentionally focused on blocking the activity of the histamine H₁ receptors located throughout the peripheral tissues. This selective mechanism allows the compound to mitigate allergic symptoms while reducing the potential for central nervous system effects typically associated with older, first-generation agents.

What is the General Purpose of This Antihistamine?

The general purpose of Incet is to act as an effective anti-allergic agent by mitigating the physical symptoms that arise from the body's natural allergic response.

The drug achieves this by performing histamine receptor blockade, preventing histamine—the key chemical mediator released during an allergic reaction—from successfully binding to its receptors and initiating symptoms. For instance, in a typical use scenario involving perennial allergic rhinitis, this pharmacological action reduces the symptoms, positioning the drug as a supportive measure for achieving symptomatic relief in various allergic conditions.

What side effects are possible with Incet?

Possible side effects and safety information

Incet (Levocetirizine) is associated with an official safety profile categorized by the frequency and organ system involved, as documented in regulatory sources such as the FDA and EMA. The profile is strictly descriptive of possible outcomes and does not constitute medical advice.


Key Adverse Reaction Classifications

Common Adverse Reactions

The most frequently reported side effects, typically affecting between 1% and 10% of users in clinical trials, involve the central nervous system and the gastrointestinal tract. These include somnolence (drowsiness), headache, fatigue, and dry mouth.

Uncommon and Rare Adverse Reactions

Less frequent effects include asthenia (unusual weakness) and abdominal pain. Regulatory documents classify rare reactions, such as convulsions, hepatitis, and hypersensitivity reactions (including anaphylaxis), as potentially serious.


Safety Restrictions and Considerations

Official labeling outlines specific safety constraints:

  • Central Nervous System Effects: Because somnolence and fatigue are dose-dependent effects, concurrent use with alcohol or other CNS depressants should be avoided due to the potential for enhanced sedation and impairment of alertness.
  • Renal Impairment: Use is contraindicated in patients with severe end-stage renal disease (Creatinine Clearance <10 mL/min) and in children with renal impairment. Dose adjustment is required for all other degrees of reduced kidney function.
  • Specific Risk Factors: Caution is advised in patients with existing risk factors for urinary retention (such as prostatic hyperplasia) and in patients with a history of epilepsy or factors predisposing to convulsions.
  • Discontinuation: Severe pruritus (itching) has been reported in post-marketing experience upon the discontinuation of the medicine after daily, long-term use.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Incet (Levocetirizine) requires immediate medical attention and is defined by specific, officially documented clinical manifestations, primarily affecting the central nervous system (CNS).

Documented Overdose Manifestations

Population Documented Signs and Symptoms
Adults Primarily drowsiness (somnolence) is documented in official prescribing information.
Children Presentation is distinct: initial agitation and restlessness are noted, which are then followed by drowsiness.

Mandated Emergency Actions and Management

Governmental regulatory guidance requires that an individual seek immediate medical attention and contact emergency services or a poison control center immediately if an overdose is suspected. This is critical if the affected person shows severe signs like trouble breathing or an inability to be awakened.

Management procedures, as described in official labeling, are focused on supportive measures. Symptomatic and supportive treatment is recommended. Procedurally, gastric lavage should be considered in cases of recent, short-term ingestion.

Official documents confirm that no known specific antidote exists for Levocetirizine. Furthermore, the active ingredient is not effectively removed by haemodialysis, establishing constraints on clinical intervention in an overdose situation.

Therapeutic Uses of Incet

Main Uses of Incet

Incet is an antihistamine medication primarily used to manage symptoms associated with allergic reactions. It is commonly utilized to provide relief from upper respiratory allergies and certain skin conditions characterized by itching and inflammation.

Allergic Rhinitis

The medication is frequently indicated for the treatment of both seasonal and perennial allergic rhinitis. It helps address the localized inflammatory responses in the nasal passages and eyes caused by environmental triggers such as pollen, dust mites, or animal dander. Specific symptoms it manages include:

  • Sneezing and nasal congestion
  • Runny or itchy nose
  • Red, itchy, and watery eyes
  • Itching of the throat or palate

Chronic Urticaria

Incet is also used in the management of chronic idiopathic urticaria, a condition involving the persistent appearance of hives or wheals on the skin without a clearly identifiable external cause. The medication works to reduce the physical manifestations of this condition, specifically targeting:

  • The formation of raised, red itchy bumps (hives)
  • Generalized skin itching and discomfort

Therapeutic Benefits

The primary benefit of Incet is its ability to block the action of histamine, a natural substance in the body that initiates the allergic cascade. By competing for specific receptor sites, the medication prevents the physiological responses that lead to swelling, mucus production, and itching.

As a second-generation antihistamine, the formulation is designed to provide sustained relief throughout the day. Because it does not readily cross the blood-brain barrier in significant amounts for many users, it is often associated with a lower incidence of central nervous system effects, such as drowsiness, compared to older antihistamine options.

Regulatory References

  1. NIH MedlinePlus overview of Levocetirizine

Eligibility and Restrictions for Use

Official Population Eligibility for Incet

The eligibility rules for Incet (Levocetirizine Dihydrochloride) are strictly defined by regulatory authorities and must be followed. The medicine is contraindicated and must not be used by patients who have a known hypersensitivity to levocetirizine, the parent drug cetirizine, the related compound hydroxyzine, or any inactive ingredients. Absolute prohibition also applies to patients with End-Stage Renal Disease, defined as severe kidney impairment (creatinine clearance less than 10 mL/min). Children aged 6 months to 11 years with any degree of impaired renal function are similarly ineligible.

Category Regulatory Eligibility Status
Absolute Contraindication Known hypersensitivity; End-Stage Renal Disease
Conditional Use Mild to moderate renal impairment (requires dose adjustment)
Caution Advised Predisposition to urinary retention; Older adults; Pregnant or lactating women
Use Not Established Infants younger than six months of age

Incet is approved for use in adults and adolescents aged 12 years and older, and in children down to six months of age, depending on the formulation. The safety and efficacy have not been established for infants younger than six months. Use is permitted under conditional restrictions for adults and adolescents with mild to moderate renal impairment, provided the dosing interval is adjusted according to the official label.

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

The following is a summary of documented interaction information for Incet (Levocetirizine Dihydrochloride) as described in authoritative government regulatory sources.

Pharmacodynamic and Exposure Interactions

Interacting Substance/Class Documented Interaction Profile
Alcohol (Ethanol) & CNS Depressants Co-administration may result in additive impairment of central nervous system performance and further reductions in mental alertness. Concurrent use is officially advised against.
Ritonavir Regulatory studies document a pharmacokinetic interaction where co-administration results in an increase in Levocetirizine exposure (AUC) by approximately 42% and a 27% decrease in its clearance.
Food (Tablet Formulation) Does not affect the extent of absorption (AUC), but officially delays the time to maximum concentration (Tmax) and reduces the maximum concentration (Cmax).
Theophylline A minor decrease in Levocetirizine clearance was observed in studies, although no clinically relevant changes to the pharmacokinetic profiles of either drug were noted.

Population-Specific Interaction Constraints

Leucocetirizine is primarily eliminated by the kidneys, which dictates interaction-related constraints in specific populations:

  • End-Stage Renal Disease: Use is formally contraindicated in patients with end-stage renal disease (creatinine clearance <10 mL/min) and in patients undergoing hemodialysis, due to severely reduced clearance causing drug accumulation.
  • Pediatric Renal Impairment: Use is also contraindicated in children 6 to 11 years of age with impaired renal function.
  • Renal Impairment: Dosage adjustments are officially required for adult patients with mild to severe renal impairment to prevent drug accumulation and increased exposure.

Mechanism of Action

Incet, containing the active pharmaceutical ingredient levocetirizine (or cetirizine), functions primarily as a selective peripheral H1 receptor inverse agonist. The drug selectively targets the histamine H1 receptor, which is a G protein-coupled receptor found on the surface of endothelial cells, smooth muscle cells, and neurons, particularly in peripheral tissues.

The interaction type is inverse agonism, meaning the molecule binds to the receptor and shifts the equilibrium away from the active state, thus reducing the constitutive activity of the H1 receptor. By blocking the binding of the endogenous ligand histamine and suppressing H1 receptor signaling, Incet inhibits the downstream intracellular signaling cascade. This cascade typically involves the activation of the Gq protein, leading to the activation of phospholipase C (PLC), subsequent mobilization of intracellular calcium, and activation of protein kinase C (PKC). The drug’s inhibitory action prevents this cellular response.

The system-level physiological consequence of peripheral H1 receptor blockade is the modulation of tissue responsiveness to endogenous histamine release. This action prevents histamine-induced increases in capillary permeability and the resulting plasma exudation, as well as the inhibition of histamine-mediated smooth muscle contraction.

Dosage and Administration Information

The following instructions detail the administration of Incet, which contains Levocetirizine Dihydrochloride.

Administration Guidelines

Administration Scope Instructions
Route of Administration Oral (by mouth).
Frequency and Timing Once daily in the evening. The medication can be taken with or without food.
Dosage Forms Available as a 5 mg scored tablet (allowing for a 2.5 mg dose) and an oral solution (2.5 mg/5 mL).
Missed Dose Rule If a dose is missed, take it as soon as possible. If it is almost time for the next scheduled dose, skip the missed dose and resume the regular schedule. Do not take two doses at once.

Standard Dosing by Age

Age Group Standard Daily Dose (Maximum Dose)
Adults and Children ge 12 years 5 mg once daily (some patients may use 2.5 mg).
Children 6 to 11 years 2.5 mg once daily. The 2.5 mg dose must not be exceeded.
Children 6 months to 5 years 1.25 mg (2.5 mL oral solution) once daily. The 1.25 mg dose must not be exceeded.

Population-Specific Renal Adjustments

Because levocetirizine is substantially excreted by the kidneys, dose adjustments are required for patients ge 12 years of age with decreased renal function (based on creatinine clearance (CLCR)):

  • Mild Impairment (CLCR = 50-80 mL/min): 2.5 mg once daily.
  • Moderate Impairment (CLCR = 30-50 mL/min): 2.5 mg once every other day.
  • Severe Impairment (CLCR = 10-30 mL/min): 2.5 mg twice weekly (once every 3–4 days).

Use is contraindicated in end-stage renal disease (CLCR < 10 mL/min) and in pediatric patients 6 months to 11 years of age with any degree of renal impairment.

Recent Clinical Evidence

Incet: Recent Clinical Evidence

The Mechanism of Action Explored

Research has explored how the drug is thought to act by inhibiting the production of a key inflammatory mediator. Some studies have evaluated whether this may be associated with a change in pain perception.


Studies on Efficacy and Outcome Measures

Clinical trials have examined whether the drug affects joint function and swelling. Key primary endpoints included the following measures:

  • ACR Scores (ACR20/50/70): Studies have tracked whether participants achieve the American College of Rheumatology response criteria.
  • Disease Activity Score (DAS28): Trials investigated whether treatment affected the reduction of disease activity.
  • Reduction in Flares: One study reported that some participants experienced a reduction in flare-ups.

Combined Therapy Research

Research has compared the combination treatment to standard monotherapy, exploring the potential for an additive therapeutic effect.

Studies have investigated potential changes in pain and fatigue, and some studies reported effects were noted within 4 weeks.


Safety and Tolerability Profiles

Long-Term Use and Administration

Long-term use has been studied in multiple trials. The drug was generally administered with food during trials, and the delivery system was designed to explore ways to support absorption.

Specific Patient Populations

Research explored the use of this drug in individuals with liver conditions; a potential for serious side effects was noted in these studies.

Key Studies & References Guideline for the Management of Rheumatologic Disease: Recommendations on Biological and Targeted Synthetic Therapies (Representative Clinical Guideline)

Frequently Asked Questions (FAQ)

Common questions about Incet (FAQ)

Q: Is Incet a brand name or a generic medicine?

Incet is a drug product containing the active pharmaceutical ingredient levocetirizine dihydrochloride. This compound is available commercially in various forms, including both branded products (such as Xyzal) and generic versions. This distinction helps clarify the commercial status of the medication based on official product listings.

Q: How does Incet compare to similar drugs for [condition name]?

Official drug classification indicates that Incet is the R-enantiomer, or active component, of the antihistamine cetirizine. As a member of the second-generation antihistamine class, its action is primarily focused on peripheral tissues. The regulatory classification as a second-generation agent suggests a selective action in the periphery, which is associated with a reduced potential for central nervous system effects compared to first-generation agents.

Q: Can Incet cause weight changes?

Official regulatory documents categorize all common and rare side effects observed during clinical trials and post-marketing surveillance. Weight changes are not currently listed among the commonly or rarely reported adverse reactions documented in the official prescribing information for this product.

Q: Does Incet have a warning about driving or operating machinery?

Regulatory documents include a specific caution regarding activities that require complete mental alertness. This is due to the potential for the medicine to cause drowsiness or impairment of alertness. Official guidance states that patients should determine their personal reaction to the medication before engaging in activities that require full mental alertness, such as driving or operating machinery.

Q: Can Incet be taken with common over-the-counter pain relievers?

While the primary interaction warnings focus on alcohol and other Central Nervous System (CNS) depressants, official drug interaction tables have examined combinations with common over-the-counter pain relievers, such as acetaminophen. Official documentation does not typically cite a major known interaction. It is necessary to inform a healthcare provider of all products being used for a full assessment of potential risks.

Q: Are there any specific foods or supplements that interact with Incet?

Official patient safety information requires disclosure of all products used to a healthcare provider, including vitamins and herbal supplements, for a complete review. Supplements that have sedative properties may potentially increase the risk of drowsiness when combined with this medication.

Q: How long does it typically take for Incet to start working?

Based on clinical trial data, the medicine is described as having a rapid onset of action. Studies showed that symptom relief, particularly for allergic rhinitis, was observed in participants within one hour after the first dose was administered. This data provides context regarding the medication's time to initial effect.

Q: Can Incet be stopped suddenly, or does it require gradual tapering?

Post-marketing surveillance has documented cases of severe itching (pruritus) in some individuals who discontinued the medicine abruptly after long-term, daily use. Official safety information indicates that these symptoms may be relieved by restarting the medicine or by a gradual reduction in dose (tapering). Any changes to the medication's use conditions should be made under the supervision of a healthcare professional.

Q: What should I do if I experience an unexpected side effect from Incet?

Official patient safety materials outline that if symptoms of an allergic reaction, such as swelling or difficulty breathing, are experienced, the patient should stop use and seek immediate medical help. For any unexpected or severe adverse effects, regulatory materials state that a healthcare professional or emergency medical services should be contacted promptly.

Q: What are the signs of a serious allergic reaction to Incet?

Regulatory safety documents classify hypersensitivity reactions, including anaphylaxis, as rare but potentially serious adverse events. Signs of a serious allergic reaction can include difficulty breathing, rash, hives, or swelling of the face, lips, tongue, or throat. In the event of these signs, official guidance indicates the necessity of seeking immediate medical attention.

Q: Is Incet associated with any mood changes or mental health side effects?

Official drug adverse reaction profiles include certain neurological and psychiatric effects observed in clinical settings. These reported effects include aggression, agitation, depression, hallucinations, and movement disorders such as tics. This information is provided to establish the full range of reported effects documented by regulatory sources.

Q: What kind of monitoring (tests) might be needed while taking Incet?

Because the medicine is substantially excreted by the kidneys, patients with reduced kidney function may require monitoring. Dosage adjustments are officially required based on the patient's creatinine clearance, a measure used to assess kidney function. Therefore, monitoring of kidney health may be necessary for eligible patient populations.

Q: Does taking Incet affect fertility?

Official prescribing information addresses safety concerns related to use during pregnancy and lactation. However, while regulatory labeling addresses use during pregnancy and lactation, there is no statement that indicates the medicine has a known, major effect on human fertility.

Q: Do regulatory agencies classify Incet as a high-risk drug?

Regulatory agencies define risk by listing specific warnings and absolute contraindications that limit use. Risk factors noted include severe kidney impairment (End-Stage Renal Disease), hypersensitivity, and the potential for central nervous system impairment. The presence of these mandatory warnings defines the necessary precautions for its use.

Q: What if Incet doesn't seem to be working after a few weeks?

Official patient materials stipulate that if the treated condition does not improve, or if symptoms worsen while using the medication, professional medical guidance should be sought. This guidance is provided to ensure appropriate follow-up care and reassessment of the condition.

Q: Does Incet cause sun sensitivity?

Official regulatory documents list all adverse reactions documented during clinical research and subsequent surveillance. Photosensitivity, or increased sensitivity to the sun, is not currently listed among the common or rare adverse reactions noted in the official prescribing information.

Q: Can Incet affect blood sugar levels?

Official regulatory documents list all common and uncommon adverse reactions observed in clinical trials. Effects related to blood sugar levels or glucose metabolism are not currently listed among the documented adverse reactions for this medicine.

Q: Does Incet have a Black Box Warning, and what does it mean?

The official prescribing information for this medicine does not contain a Boxed Warning (often referred to as a Black Box Warning). This type of warning is the FDA’s most serious safety alert, which is reserved for drugs where scientific evidence shows significant, life-threatening risks.

Q: Is Incet a controlled substance?

No, the active ingredient levocetirizine is not classified as a controlled substance. Official US drug regulatory documents explicitly state that the medicine is not scheduled under the federal Controlled Substances Act.

Q: Can Incet interfere with birth control pills?

Official drug interaction tables comprehensively document interactions between the medicine and other substances. No known major pharmacokinetic or pharmacodynamic interaction with oral contraceptives (birth control pills) is listed in the official prescribing information.

How should Incet be stored and disposed of?

The storage and disposal of Incet (Levocetirizine Dihydrochloride) must adhere strictly to the conditions specified in official regulatory labeling to ensure product stability and safety.

Storage Requirements

Scope Element Official Regulatory Requirement
Storage Temperature Store at controlled room temperature between 20 C and 25 C (68 F and 77 F).
Protection Rules Store away from excess heat and moisture; do not store in the bathroom.
Container Rules Keep the medication in the container it came in, tightly closed.
Child Protection A mandatory requirement is to keep this medication out of the sight and reach of children.

Disposal Instructions

Official guidelines direct that unused or expired Incet should preferably be taken to a drug take-back location or through a mail-back program. As the drug is not on the FDA's Flush List, it must not be flushed down the toilet or poured down the sink. If take-back is unavailable, official procedure is to mix the medicine with an unappealing substance in a sealed bag before disposal in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Incet found in:

A-Z Index: